<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01605435</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 814309</org_study_id>
    <nct_id>NCT01605435</nct_id>
  </id_info>
  <brief_title>Ghrelin Dose Finding In Frail Elderly</brief_title>
  <official_title>Ghrelin In Frail Elderly Subcutaneous Dose Finding Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Frailty is a geriatric syndrome leading to physical deterioration including muscle wasting
      (sarcopenia) and unintentional weight loss. There are currently no approved therapies for
      frailty. Ghrelin is a hormone produced by the stomach that stimulates appetite centers in the
      brain. The purpose of this study is to determine the optimal subcutaneous ghrelin dose as a
      potential intervention for frail elderly individuals. We will examine food intake and
      metabolic parameters after placebo and ghrelin administration at three escalating
      subcutaneously administered doses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is to determine the optimal ghrelin dose for use in a daily subcutaneous dosing
      study in frail individuals. Using data from our previous study and the published literature,
      we have designed a single blind, single dose administration study in which we will examine
      food intake after ghrelin administration and metabolic parameters (plasma glucose, insulin,
      free fatty acids, and cortisol) pre and post ghrelin administration.We have selected a dose
      range using our own and previously published studies from which we will determine
      subcutaneous doses to use in subsequent studies. The selection criteria for subsequent
      studies will be the dose that maximizes food intake by more than 30% without inducing
      hyperglycemia or raising cortisol levels. Participants must meet all inclusion criteria and
      have no exclusion criteria. Data will be analyzed after the first three participants have
      completed the protocol and used to inform dose modifications for the next three participants.
      Data from this portion of the study will be analyzed immediately after its completion, to
      allow updates to the design of the next study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Emergent Adverse Events</measure>
    <time_frame>30 days following the last administration of study treatment.</time_frame>
    <description>Number and type of treatment emergent adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Energy Intake</measure>
    <time_frame>30 mins post-ghrelin or placebo</time_frame>
    <description>Median energy intake at breakfast, which was served 30 minutes post-placebo or ghrelin administration demonstrated at each dose level.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Total Energy Intake Relative to Placebo</measure>
    <time_frame>30 mins post-ghrelin or placebo</time_frame>
    <description>% of total energy relative to placebo - breakfast served 30 minutes post-placebo or ghrelin administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Growth Hormone</measure>
    <time_frame>30 minutes after ghrelin administration</time_frame>
    <description>median growth hormone peak 30 minutes after placebo/ghrelin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cortisol Level</measure>
    <time_frame>0, 60 and 120 minutes after dosing</time_frame>
    <description>Cortisol response to ghrelin or placebo - levels at 0, 60 and 120 minutes after dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glucose Levels</measure>
    <time_frame>0 minutes (baseline) and 60 or 90 minutes from dosing</time_frame>
    <description>Median fasting and peak postprandial Glucose levels (60 or 90 minutes from dosing) at placebo and at each ghrelin dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin Level</measure>
    <time_frame>0 and 90 minutes after dosing</time_frame>
    <description>Median fasting insulin levels at baseline and 90 minutes after dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Free Fatty Acid Level</measure>
    <time_frame>90 and 120 minutes after dosing</time_frame>
    <description>Free Fatty Acid levels (mEq/L) at 60 and 90 minutes after meal (90 and 120 minutes)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>The Frailty Syndrome</condition>
  <arm_group>
    <arm_group_label>Ghrelin Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose finding with each of the first two participant coming to the CTRC for four visits greater than or equal to 72 hours apart and on each receiving subcutaneous injection of - placebo (first visit) and three escalating doses of ghrelin 2ug/kg (second visit) , 5 ug/kg (third visit), and 10 ug/kg (fourth visit).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ghrelin Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose finding with each of the final three participant coming to the CTRC for four visits greater than or equal to 72 hours apart and on each receiving subcutaneous injection of - placebo (first visit) and three escalating doses of ghrelin 5ug/kg (second visit) , 7.5 ug/kg (third visit), and 10 ug/kg (fourth visit).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ghrelin Group 1</intervention_name>
    <description>The first two participants received placebo at baseline visit, 2 mcg/kg as a single subcutaneous dose at Visit 2, 5 mcg/kg as a single subcutaneous dose at Visit 3, and 10 mcg/Kg as a single subcutaneous dose at visit 4. There was 3-10 days between visits.</description>
    <arm_group_label>Ghrelin Group 1</arm_group_label>
    <other_name>First dose escalation group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ghrelin Group 2</intervention_name>
    <description>The next three participants received placebo at baseline visit, 5 mcg/kg as a single subcutaneous dose at Visit 2, 7.5 mcg/kg as a single subcutaneous dose at Visit 3, and 10 mcg/Kg as a single subcutaneous dose at visit 4.</description>
    <arm_group_label>Ghrelin Group 2</arm_group_label>
    <other_name>Second dose escalation group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  We will include men and women aged 70 or older who are able to provide informed
             consent and are frail by the Fried criteria (Table 1).

          -  Table 1. Frailty criteria. Individuals with three, four, or all five criteria are
             frail.

          -  Weight loss: Unintentional weight loss of &gt;5% over the previous year

        Exhaustion: Two statements are read:

          -  I felt that everything I did was an effort

          -  I could not get going. The question is asked &quot;How often in the last week did you feel
             this way?&quot; 0 = rarely or none of the time (&lt;1 day), 1 = some or a little of the time
             (1-2 days), 2 = a moderate amount of the time (3-4 days), or 3 = most of the time. A
             &quot;2&quot; or &quot;3&quot; response to either question is a positive response.

               -  Low physical activity: Kcal/week of physical activity calculated from the short
                  version of the Minnesota Leisure Time Activity questionnaire.40 &lt; 383 kcals in
                  men or &lt; 270 kcals/wk in women is positive for this criterion.

               -  Slow walking speed: A usual pace, 15-ft walk timed from a defined standing start.
                  For men ≤173 cm tall and women ≤159 cm, ≥7 sec, and for men &gt;173 cm and women &gt;
                  159 cm, ≥ 6 sec is positive for this criterion.

               -  Weakness: Hand grip strength measured with a dynamometer. The average of three
                  measurements performed in the dominant hand is used. For men with BMI ≤ 24 kg/m2,
                  the cutoff is ≤ 29 kg, for BMI 24.1 to 26 the cutoff is ≤ 30 kg, for BMI 26.1 to
                  28 the cutoff is ≤30 kg, and for BMI &gt; 28 the cutoff is ≤ 32 kg. For women with
                  BMI ≤ 23 kg/m2, the cutoff is ≤ 17 kg, for BMI 23.1 to 26 the cutoff is ≤ 17.3
                  kg, for BMI 26.1 to 29 the cutoff is ≤ 18 kg, and for BMI &gt; 29 the cutoff is ≤ 21
                  kg for a positive criterion.

        Exclusion Criteria:

          1. Diabetes mellitus or fasting glucose ≥ 126 mg/dL

          2. Hospitalization for stroke, myocardial infarction, coronary artery bypass graft
             surgery, vascular surgery in the past six months.

          3. NYHA Class III or IV congestive heart failure

          4. Therapy for cancer in the past 12 months, except non-melanoma skin cancer

          5. BMI≥ 30 kg/m2

          6. Current use of corticosteroids other than topical, ophthalmic, and inhaled
             preparations

          7. Therapy with megestrol acetate or dronabinol within the last 6 weeks

          8. TSH measured as &lt;0.4 mU/L or greater than 10mU/L

          9. Abnormal liver function tests (LFTs &gt; 2x upper limit of normal)

         10. Hemoglobin &lt; 11g/dL

         11. Insulin-like growth factor-I (IGF-I) above the age-specific reference range

         12. History of surgery within the last 30 days

         13. Unstable medical or psychological conditions or unstable home or food environment

         14. Cognitive deficit as defined by a Folstein Mini Mental State Exam score &lt; 18/30

         15. Depression (defined as a score of &gt;11 on the Geriatric Depression Questionnaire)

             -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne R. Cappola, M.D., Sc.M.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Of Pennsylvania, Perelman School of Medicine, Department of Endocrinology, Diabetes and Metabolism</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical and Translational Research Center, University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>May 22, 2012</study_first_submitted>
  <study_first_submitted_qc>May 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2012</study_first_posted>
  <results_first_submitted>September 12, 2014</results_first_submitted>
  <results_first_submitted_qc>September 10, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 10, 2018</results_first_posted>
  <last_update_submitted>November 26, 2019</last_update_submitted>
  <last_update_submitted_qc>November 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Anne Cappola</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Frailty</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study participants were recruited from community dwelling adults meeting study criteria expressing interest in participating in research studies at University of Pennsylvania.</recruitment_details>
      <pre_assignment_details>Dose finding with each participant receiving placebo at their first study visits and three escalating doses of ghrelin, separated by 3-7 days in visits 2,3 and 4.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Initial Dosing Group</title>
          <description>Visit 1: Placebo Visit 2: 2 ug/kg ghrelin Visit 3: 5 ug/kg ghrelin Visit 4: 10 ug/kg ghrelin</description>
        </group>
        <group group_id="P2">
          <title>Second Dosing Group</title>
          <description>Visit 1: Placebo Visit 2: 5 ug/kg ghrelin Visit 3: 7.5 ug/kg ghrelin Visit 4: 10 ug/kg ghrelin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ghrelin</title>
          <description>Dose finding with each participant receiving placebo and three doses of ghrelin, separated by 3-7 days
Ghrelin: The first three participants will receive 2 mcg/kg as a single subcutaneous dose at Visit 3, 5 mcg/kg as a single subcutaneous dose at Visit 4, and 10 mcg/Kg as a single subcutaneous dose at visit 5. There will be 3-10 days between visits. The next three participants will receive either the same dosing at the first three, a regimen that includes an intermediate dose (e.g., 7.5 mcg/kg), or higher (e.g., 12, 15, and 18 mcg/kg) doses.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85" lower_limit="79" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Treatment Emergent Adverse Events</title>
        <description>Number and type of treatment emergent adverse events</description>
        <time_frame>30 days following the last administration of study treatment.</time_frame>
        <population>At the first visit all participants received s.c. placebo. The first two participants received 2 ,5, and 10ug/kg of ghrelin at visit 2,3 and 4 consecutively. The final three participants received 5,7.5, and 10ug/kg of s.c. ghrelin at visits 2,3 and 4 consecutively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>All 5 subjects received s.c. placebo at visit 1.</description>
          </group>
          <group group_id="O2">
            <title>2ug/kg</title>
            <description>The first two participants received 2ug/kg of s.c. ghrelin at visit 2.</description>
          </group>
          <group group_id="O3">
            <title>5ug/kg</title>
            <description>The first two participants received 5ug/kg of s.c. ghrelin at visit 3. The final three participants received 5ug/kg of s.c. ghrelin at visits 2.</description>
          </group>
          <group group_id="O4">
            <title>7.5ug/kg</title>
            <description>The final three participants received 7.5ug/kg of s.c. ghrelin at visit 3.</description>
          </group>
          <group group_id="O5">
            <title>10ug/kg</title>
            <description>The first two participants received 10ug/kg of s.c. ghrelin at visit 4. The final three participants received 10ug/kg of s.c. ghrelin at visit 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Emergent Adverse Events</title>
          <description>Number and type of treatment emergent adverse events</description>
          <population>At the first visit all participants received s.c. placebo. The first two participants received 2 ,5, and 10ug/kg of ghrelin at visit 2,3 and 4 consecutively. The final three participants received 5,7.5, and 10ug/kg of s.c. ghrelin at visits 2,3 and 4 consecutively.</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>burping</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sensation of warmth</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>bristley feeling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>dizzy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>awareness of old incision</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>euphoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Median Energy Intake</title>
        <description>Median energy intake at breakfast, which was served 30 minutes post-placebo or ghrelin administration demonstrated at each dose level.</description>
        <time_frame>30 mins post-ghrelin or placebo</time_frame>
        <population>At the first visit all participants received s.c. placebo. The first two participants received 2 ,5, and 10ug/kg of ghrelin at visit 2, 3 and 4 consecutively. The final three participants received 5,7.5, and 10ug/kg of s.c. ghrelin at visits 2,3 and 4 consecutively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>All 5 subjects received s.c. placebo at visit 1.</description>
          </group>
          <group group_id="O2">
            <title>2 mcg/kg</title>
            <description>The first two participants received 2ug/kg of s.c. ghrelin at visit 2.</description>
          </group>
          <group group_id="O3">
            <title>5mcg/kg</title>
            <description>The first two participants received 5ug/kg of s.c. ghrelin at visit 3. The final three participants received 5ug/kg of s.c. ghrelin at visits 2.</description>
          </group>
          <group group_id="O4">
            <title>7.5mcg/kg</title>
            <description>The final three participants received 7.5ug/kg of s.c. ghrelin at visit 3.</description>
          </group>
          <group group_id="O5">
            <title>10mcg/kg</title>
            <description>The first two participants received 10ug/kg of s.c. ghrelin at visit 4. The final three participants received 10ug/kg of s.c. ghrelin at visit 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Energy Intake</title>
          <description>Median energy intake at breakfast, which was served 30 minutes post-placebo or ghrelin administration demonstrated at each dose level.</description>
          <population>At the first visit all participants received s.c. placebo. The first two participants received 2 ,5, and 10ug/kg of ghrelin at visit 2, 3 and 4 consecutively. The final three participants received 5,7.5, and 10ug/kg of s.c. ghrelin at visits 2,3 and 4 consecutively.</population>
          <units>Kilocalories</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="535.16" lower_limit="482.14" upper_limit="670.05"/>
                    <measurement group_id="O2" value="578" lower_limit="436.28" upper_limit="719.872"/>
                    <measurement group_id="O3" value="813" lower_limit="500.87" upper_limit="1083.75"/>
                    <measurement group_id="O4" value="852" lower_limit="790.26" upper_limit="917.69"/>
                    <measurement group_id="O5" value="862.04" lower_limit="493.34" upper_limit="925.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Total Energy Intake Relative to Placebo</title>
        <description>% of total energy relative to placebo - breakfast served 30 minutes post-placebo or ghrelin administration.</description>
        <time_frame>30 mins post-ghrelin or placebo</time_frame>
        <population>At the first visit all participants received s.c. placebo. The first two participants received 2 ,5, and 10ug/kg of ghrelin at visit 2,3 and 4 consecutively. The final three participants received 5,7.5, and 10ug/kg of s.c. ghrelin at visits 2,3 and 4 consecutively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>All 5 subjects received s.c. placebo at visit 1.</description>
          </group>
          <group group_id="O2">
            <title>2 mcg/kg</title>
            <description>The first two participants received 2ug/kg of s.c. ghrelin at visit 2.</description>
          </group>
          <group group_id="O3">
            <title>5mcg/kg</title>
            <description>The first two participants received 5ug/kg of s.c. ghrelin at visit 3. The final three participants received 5ug/kg of s.c. ghrelin at visits 2.</description>
          </group>
          <group group_id="O4">
            <title>7.5mcg/kg</title>
            <description>The final three participants received 7.5ug/kg of s.c. ghrelin at visit 3.</description>
          </group>
          <group group_id="O5">
            <title>10mcg/kg</title>
            <description>The first two participants received 10ug/kg of s.c. ghrelin at visit 4. The final three participants received 10ug/kg of s.c. ghrelin at visit 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Total Energy Intake Relative to Placebo</title>
          <description>% of total energy relative to placebo - breakfast served 30 minutes post-placebo or ghrelin administration.</description>
          <population>At the first visit all participants received s.c. placebo. The first two participants received 2 ,5, and 10ug/kg of ghrelin at visit 2,3 and 4 consecutively. The final three participants received 5,7.5, and 10ug/kg of s.c. ghrelin at visits 2,3 and 4 consecutively.</population>
          <units>percentage of placebo intake</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="110"/>
                    <measurement group_id="O3" value="135"/>
                    <measurement group_id="O4" value="139"/>
                    <measurement group_id="O5" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Growth Hormone</title>
        <description>median growth hormone peak 30 minutes after placebo/ghrelin.</description>
        <time_frame>30 minutes after ghrelin administration</time_frame>
        <population>At the first visit all participants received s.c. placebo. The first two participants received 2 ,5, and 10ug/kg of ghrelin at visit 2,3 and 4 consecutively. The final three participants received 5,7.5, and 10ug/kg of s.c. ghrelin at visits 2,3 and 4 consecutively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>All 5 subjects received s.c. placebo at visit 1.</description>
          </group>
          <group group_id="O2">
            <title>2mcg/kg</title>
            <description>The first two participants received 2ug/kg of s.c. ghrelin at visit 2.</description>
          </group>
          <group group_id="O3">
            <title>5mcg/kg</title>
            <description>The first two participants received 5ug/kg of s.c. ghrelin at visit 3. The final three participants received 5ug/kg of s.c. ghrelin at visits 2.</description>
          </group>
          <group group_id="O4">
            <title>7.5mcg/kg</title>
            <description>The final three participants received 7.5ug/kg of s.c. ghrelin at visit 3.</description>
          </group>
          <group group_id="O5">
            <title>10mcg/kg</title>
            <description>The first two participants received 10ug/kg of s.c. ghrelin at visit 4. The final three participants received 10ug/kg of s.c. ghrelin at visit 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Growth Hormone</title>
          <description>median growth hormone peak 30 minutes after placebo/ghrelin.</description>
          <population>At the first visit all participants received s.c. placebo. The first two participants received 2 ,5, and 10ug/kg of ghrelin at visit 2,3 and 4 consecutively. The final three participants received 5,7.5, and 10ug/kg of s.c. ghrelin at visits 2,3 and 4 consecutively.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.71" lower_limit="2.52" upper_limit="5.91"/>
                    <measurement group_id="O2" value="16.87" lower_limit="4.27" upper_limit="29.47"/>
                    <measurement group_id="O3" value="31.81" lower_limit="7.85" upper_limit="50.00"/>
                    <measurement group_id="O4" value="39.20" lower_limit="12.20" upper_limit="39.21"/>
                    <measurement group_id="O5" value="33.63" lower_limit="4.99" upper_limit="50.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cortisol Level</title>
        <description>Cortisol response to ghrelin or placebo - levels at 0, 60 and 120 minutes after dosing</description>
        <time_frame>0, 60 and 120 minutes after dosing</time_frame>
        <population>At the first visit all participants received s.c. placebo. The first two participants received 2 ,5, and 10ug/kg of ghrelin at visit 2,3 and 4 consecutively. The final three participants received 5,7.5, and 10ug/kg of s.c. ghrelin at visits 2,3 and 4 consecutively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>All 5 subjects received s.c. placebo at visit 1.</description>
          </group>
          <group group_id="O2">
            <title>2ug/kg</title>
            <description>The first two participants received 2ug/kg of s.c. ghrelin at visit 2.</description>
          </group>
          <group group_id="O3">
            <title>5ug/kg</title>
            <description>The first two participants received 5ug/kg of s.c. ghrelin at visit 3. The final three participants received 5ug/kg of s.c. ghrelin at visits 2.</description>
          </group>
          <group group_id="O4">
            <title>7.5ug/kg</title>
            <description>The final three participants received 7.5ug/kg of s.c. ghrelin at visit 3.</description>
          </group>
          <group group_id="O5">
            <title>10ug/kg</title>
            <description>The first two participants received 10ug/kg of s.c. ghrelin at visit 4. The final three participants received 10ug/kg of s.c. ghrelin at visit 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Cortisol Level</title>
          <description>Cortisol response to ghrelin or placebo - levels at 0, 60 and 120 minutes after dosing</description>
          <population>At the first visit all participants received s.c. placebo. The first two participants received 2 ,5, and 10ug/kg of ghrelin at visit 2,3 and 4 consecutively. The final three participants received 5,7.5, and 10ug/kg of s.c. ghrelin at visits 2,3 and 4 consecutively.</population>
          <units>mcg/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 minutes, baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.4" lower_limit="19.3" upper_limit="35.2"/>
                    <measurement group_id="O2" value="27.1" lower_limit="24.5" upper_limit="29.7"/>
                    <measurement group_id="O3" value="28.4" lower_limit="20.6" upper_limit="30.4"/>
                    <measurement group_id="O4" value="21.5" lower_limit="20.7" upper_limit="28.6"/>
                    <measurement group_id="O5" value="22.7" lower_limit="20" upper_limit="30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 minutes after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6" lower_limit="14.7" upper_limit="22.6"/>
                    <measurement group_id="O2" value="22.0" lower_limit="21.2" upper_limit="22.8"/>
                    <measurement group_id="O3" value="35.3" lower_limit="18.4" upper_limit="42.7"/>
                    <measurement group_id="O4" value="33.7" lower_limit="16.2" upper_limit="36.0"/>
                    <measurement group_id="O5" value="31.8" lower_limit="18.2" upper_limit="41.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 minutes after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8" lower_limit="16.8" upper_limit="32.8"/>
                    <measurement group_id="O2" value="29.7" lower_limit="29" upper_limit="30.4"/>
                    <measurement group_id="O3" value="27.5" lower_limit="19.0" upper_limit="37.7"/>
                    <measurement group_id="O4" value="32.5" lower_limit="17.9" upper_limit="33.0"/>
                    <measurement group_id="O5" value="26.4" lower_limit="20.5" upper_limit="30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Glucose Levels</title>
        <description>Median fasting and peak postprandial Glucose levels (60 or 90 minutes from dosing) at placebo and at each ghrelin dose.</description>
        <time_frame>0 minutes (baseline) and 60 or 90 minutes from dosing</time_frame>
        <population>At the first visit all participants received s.c. placebo. The first two participants received 2 ,5, and 10ug/kg of ghrelin at visit 2,3 and 4 consecutively. The final three participants received 5,7.5, and 10ug/kg of s.c. ghrelin at visits 2,3 and 4 consecutively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>All 5 subjects received s.c. placebo at visit 1.</description>
          </group>
          <group group_id="O2">
            <title>2mcg/kg</title>
            <description>The first two participants received 2ug/kg of s.c. ghrelin at visit 2.</description>
          </group>
          <group group_id="O3">
            <title>5mcg/kg</title>
            <description>The first two participants received 5ug/kg of s.c. ghrelin at visit 3. The final three participants received 5ug/kg of s.c. ghrelin at visits 2.</description>
          </group>
          <group group_id="O4">
            <title>7.5mcg/kg</title>
            <description>The final three participants received 7.5ug/kg of s.c. ghrelin at visit 3.</description>
          </group>
          <group group_id="O5">
            <title>10mcg/kg</title>
            <description>The first two participants received 10ug/kg of s.c. ghrelin at visit 4. The final three participants received 10ug/kg of s.c. ghrelin at visit 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose Levels</title>
          <description>Median fasting and peak postprandial Glucose levels (60 or 90 minutes from dosing) at placebo and at each ghrelin dose.</description>
          <population>At the first visit all participants received s.c. placebo. The first two participants received 2 ,5, and 10ug/kg of ghrelin at visit 2,3 and 4 consecutively. The final three participants received 5,7.5, and 10ug/kg of s.c. ghrelin at visits 2,3 and 4 consecutively.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fasting (0 minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="89" upper_limit="122"/>
                    <measurement group_id="O2" value="90" lower_limit="87" upper_limit="93"/>
                    <measurement group_id="O3" value="91" lower_limit="88" upper_limit="102"/>
                    <measurement group_id="O4" value="104" lower_limit="89" upper_limit="113"/>
                    <measurement group_id="O5" value="94" lower_limit="88" upper_limit="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>peak postprandial (60 or 90 minutes after dosing)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142" lower_limit="125" upper_limit="166"/>
                    <measurement group_id="O2" value="141" lower_limit="135" upper_limit="146"/>
                    <measurement group_id="O3" value="162" lower_limit="145" upper_limit="187"/>
                    <measurement group_id="O4" value="167" lower_limit="147" upper_limit="196"/>
                    <measurement group_id="O5" value="164" lower_limit="153" upper_limit="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Insulin Level</title>
        <description>Median fasting insulin levels at baseline and 90 minutes after dosing</description>
        <time_frame>0 and 90 minutes after dosing</time_frame>
        <population>At the first visit all participants received s.c. placebo. The first two participants received 2 ,5, and 10ug/kg of ghrelin at visit 2,3 and 4 consecutively. The final three participants received 5,7.5, and 10ug/kg of s.c. ghrelin at visits 2,3 and 4 consecutively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>All 5 subjects received s.c. placebo at visit 1.</description>
          </group>
          <group group_id="O2">
            <title>2ug/kg</title>
            <description>The first two participants received 2ug/kg of s.c. ghrelin at visit 2.</description>
          </group>
          <group group_id="O3">
            <title>5ug/kg</title>
            <description>The first two participants received 5ug/kg of s.c. ghrelin at visit 3. The final three participants received 5ug/kg of s.c. ghrelin at visits 2.</description>
          </group>
          <group group_id="O4">
            <title>7.5ug/kg</title>
            <description>The final three participants received 7.5ug/kg of s.c. ghrelin at visit 3.</description>
          </group>
          <group group_id="O5">
            <title>10ug/kg</title>
            <description>The first two participants received 10ug/kg of s.c. ghrelin at visit 4. The final three participants received 10ug/kg of s.c. ghrelin at visit 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Level</title>
          <description>Median fasting insulin levels at baseline and 90 minutes after dosing</description>
          <population>At the first visit all participants received s.c. placebo. The first two participants received 2 ,5, and 10ug/kg of ghrelin at visit 2,3 and 4 consecutively. The final three participants received 5,7.5, and 10ug/kg of s.c. ghrelin at visits 2,3 and 4 consecutively.</population>
          <units>uIU/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fasting (0 minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9" lower_limit="2.0" upper_limit="16.0"/>
                    <measurement group_id="O2" value="14.8" lower_limit="13.0" upper_limit="16.5"/>
                    <measurement group_id="O3" value="8.5" lower_limit="3.1" upper_limit="16.0"/>
                    <measurement group_id="O4" value="8.7" lower_limit="7.0" upper_limit="17.2"/>
                    <measurement group_id="O5" value="9.7" lower_limit="4.7" upper_limit="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90 minutes after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.9" lower_limit="12.9" upper_limit="164.5"/>
                    <measurement group_id="O2" value="115.8" lower_limit="76.5" upper_limit="155.0"/>
                    <measurement group_id="O3" value="109.5" lower_limit="60.1" upper_limit="186.5"/>
                    <measurement group_id="O4" value="77.6" lower_limit="38.9" upper_limit="149.0"/>
                    <measurement group_id="O5" value="85.8" lower_limit="38.8" upper_limit="186.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Free Fatty Acid Level</title>
        <description>Free Fatty Acid levels (mEq/L) at 60 and 90 minutes after meal (90 and 120 minutes)</description>
        <time_frame>90 and 120 minutes after dosing</time_frame>
        <population>At the first visit all participants received s.c. placebo. The first two participants received 2 ,5, and 10ug/kg of ghrelin at visit 2,3 and 4 consecutively. The final three participants received 5,7.5, and 10ug/kg of s.c. ghrelin at visits 2,3 and 4 consecutively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>All 5 subjects received s.c. placebo at visit 1.</description>
          </group>
          <group group_id="O2">
            <title>2mcg/kg</title>
            <description>The first two participants received 2ug/kg of s.c. ghrelin at visit 2.</description>
          </group>
          <group group_id="O3">
            <title>5mcg/kg</title>
            <description>The first two participants received 5ug/kg of s.c. ghrelin at visit 3. The final three participants received 5ug/kg of s.c. ghrelin at visits 2.</description>
          </group>
          <group group_id="O4">
            <title>7.5mcg/kg</title>
            <description>The final three participants received 7.5ug/kg of s.c. ghrelin at visit 3.</description>
          </group>
          <group group_id="O5">
            <title>10mcg/kg</title>
            <description>The first two participants received 10ug/kg of s.c. ghrelin at visit 4. The final three participants received 10ug/kg of s.c. ghrelin at visit 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Free Fatty Acid Level</title>
          <description>Free Fatty Acid levels (mEq/L) at 60 and 90 minutes after meal (90 and 120 minutes)</description>
          <population>At the first visit all participants received s.c. placebo. The first two participants received 2 ,5, and 10ug/kg of ghrelin at visit 2,3 and 4 consecutively. The final three participants received 5,7.5, and 10ug/kg of s.c. ghrelin at visits 2,3 and 4 consecutively.</population>
          <units>mEq/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>90 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" lower_limit="0.12" upper_limit="0.35"/>
                    <measurement group_id="O2" value="0.11" lower_limit="0.10" upper_limit="0.12"/>
                    <measurement group_id="O3" value="0.22" lower_limit="0.09" upper_limit="0.42"/>
                    <measurement group_id="O4" value="0.35" lower_limit="0.20" upper_limit="0.46"/>
                    <measurement group_id="O5" value="0.29" lower_limit="0.08" upper_limit="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" lower_limit="0.06" upper_limit="0.12"/>
                    <measurement group_id="O2" value="0.08" lower_limit="0.05" upper_limit="0.11"/>
                    <measurement group_id="O3" value="0.09" lower_limit="0.04" upper_limit="0.27"/>
                    <measurement group_id="O4" value="0.14" lower_limit="0.11" upper_limit="0.15"/>
                    <measurement group_id="O5" value="0.12" lower_limit="0.06" upper_limit="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Recorded from study screen through 30 days after the final study visit. Assessed systematically during study visits at time 0, 15, 30, 45, 60, 90 120, and 150 minutes after dosing and 1 day after all study visits by telephone call to subject.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Visit 1 for all five subjects placebo injected s.c. at time 0</description>
        </group>
        <group group_id="E2">
          <title>2mcg/kg</title>
          <description>Visit 2 for the first two subjects 2mcg/kg ghrelin injected s.c at time 0</description>
        </group>
        <group group_id="E3">
          <title>5mcg/kg</title>
          <description>Visit 3 for the first two subjects Visit 2 for the last three subjects 5mcg/kg ghrelin injected s.c. at time 0</description>
        </group>
        <group group_id="E4">
          <title>7.5mcg/kg</title>
          <description>Visit 3 for the last three subjects 7.5mcg/kg ghrelin injected at time 0</description>
        </group>
        <group group_id="E5">
          <title>10mcg/kg</title>
          <description>Visit 4 for all five subjects</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>burping</sub_title>
                <description>during study visit 15 minutes after meal completion</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>bristley feeling in chest</sub_title>
                <description>reported day after placebo visit, occurred and resolved in one minute with no action.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>warmth</sub_title>
                <description>passing sensation between 45 and 60 minutes from ghrelin injection resolving with no action</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>euphoria</sub_title>
                <description>passing feeling during study visit 1 hour after ghrelin administration</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <description>&quot;dizzy is too strong - woozy&quot;</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>awareness of sternotomy incision</sub_title>
                <description>occurred during visit 30 minutes after ghrelin administration and resolved within 15 minutes with no action.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Anne Cappola, PI</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>215-573-5359</phone>
      <email>acappola@mail.med.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

